Health Condition 1: I519- Heart disease, unspecified
Conditions
Interventions
Intervention1: Arm 1 (Intervention Group)
Dual Antiplatelet therapy: Drug Name: Aspirin + Clopidogrel
Dose: Aspirin 75 mg once daily + Clopidogrel 75 mg once daily
Route of Administration: Oral
Fre
Sponsors
KLE College of Pharmacy Belagavi
Eligibility
Inclusion criteria
Inclusion criteria: Patients Diagnosed with CAD receiving antiplatelet therapy (IPD & OPD) Patients aged 18 years and older of both sexes. Patients who provide informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients with known contraindications to antiplatelet therapy, such as active bleeding disorders. Patients with severe co morbid conditions that could confound study outcomes (Advanced liver disease, several renal impairment, malignancies). Patients who have undergone major surgery within the last 3 months. Pregnant or breastfeeding women. Patients with terminal illness whose life expectancy is less than 1 year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy Clinical Outcomes, Patient reported outcomes Safety Bleeding events, Adverse Drug reactions, All cause mortality Timepoint: Baseline, 03 Months, 06 Months, and 12 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| QoL WHO BREF Cost analysis Direct & Indirect costsTimepoint: Baseline, 03 Months, 06 Months, & 12 Months | — |
Countries
India
Contacts
Public ContactMandati Santhosh Reddy
KLE College of Pharmacy, Belagavi
Outcome results
None listed